NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Tracy Klein, PhD, FNP; Mark Helm, MD, MBA, FAAP; William Origer, MD; Cathy Zehrung, RPh; James Slater PharmD

Members Present by Phone: Kelly Burnett, D.O.; Dave Pass, MD; Jim Richards MD, MBA

Staff Present: Roger Citron, RPh; David Engen, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; SarahServid, PharmD; Renae Wentz, MD; Dee Weston; Trevor Douglass, DC, MPH; Brandon Wells; Jennifer Torkelson; Jennifer Bowen; Victor Rojo

Staff Present by Phone: Kathy Sentena PharmD; Megan Herink, PharmD

Audience: *Mae Kwong, Johnson & Johnson; Trent Taylor, Johnson & Johnson; Michael Moore, PhD, Otsuka Pharmaceuticals; Leslie Far, Johnson & Johnson; Darlene Bitel, Takeda; *Jeffrey Nesheim, Pharm.D., Sage Therapeutics; Troy Larsen, Sage Therapeutics; Danielle Shannon, WVP Health; Rick Frees, Vertex Pharmaceuticals; *Sami Nasrawi, Alnylam Pharmaceuticals; Jon Taylor, Alnylam Pharmaceuticals; Laura Jeffcoat, Abbvie; Steve Isaki, Lundbeck; Rick Dabner, Alnylam Pharmaceuticals; Dennis Schaffer, Genzyme; Whitney Acoba; Paul Williams; Geetika Gupta, Merck; *Dan Allen, Genzyme; Mo Yang, Jazz Pharmaceuticals; Valerie Ng, Indivior; Georgette Dzwilewski, Indivior; *Deb Profant Jazz Pharmaceuticals, *Ryan Fowler, Pfizer; Pierre Thoumsin, Heron Therapeutics; Gordon Andringa, Jazz Pharmaceuticals

(*) Provided verbal testimony

Written testimony provided: Posted to OSU Website
I. CALL TO ORDER

A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff.
B. Conflict of Interest Declaration - No new conflicts of interest were declared.
C. Approval of May 2019 minutes presented by Mr. Citron and proposal to amend agenda to change order of presentation.
   **ACTION: Motion to approve, 2nd, all in favor**
D. Department Update
   No updates
E. Legislative Update
   Dee Weston presented:
   SB 138
   - Reestablishes the mental health clinical advisory group in perpetuity
   - Expands that membership of the MHCAG to include a representative from Dept. of Corrections, the tribes, and makes formal connection to the Oregon Psychiatric Advice Line
   - Provides permanent staff support to the group
   - Expands the MG drug carve out to Jan. 1, 2022

HB 2678:

With failure of HB 2678 this past session, we are evaluating our options going forward. This requires OHA to pause efforts toward an aligned PDL, which was originally intended to begin January 1, 2020. After OHA evaluates possible options moving forward, the agency will begin working with key partners and stakeholders to determine what is the best for OHP members, their providers and OHA.

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Reports
B. CMS Annual Report
C. Inhaled Short-acting Beta-agonists Literature Scan
   **Recommendation:**
   1. Make no changes to the preferred drug list (PDL) based on clinical evidence.
   2. Evaluate comparative drug costs in executive session.
   **ACTION: Motion to approve, 2nd, all in favor**
III. DUR ACTIVIES

A. ProDUR Report - Mr. Holsapple presented the ProDUR report & Support Act implications – expand ProDUR
B. RetroDUR Report - Dr. Engen presented the RetroDUR Report
C. Oregon State Drug Reviews
   1. Non-statin Low-Density Lipoprotein Cholesterol (LDL-C) Lowering Therapy and Cardiovascular Outcomes
   2. Update on Medications Used to Manage Opioid Use Disorder and Opioid Withdrawal

Dr. Sentena presented two recently published newsletters, thanked the Committee for reviewing the draft versions and solicited ideas for future newsletters.

IV. DUR NEW BUSINESS

A. Opioid/Sedative Retrospective DUR Proposal
   Dr. Engen presented the proposal to:
   1. Send a prescriber letter to notify them of combination opioid/sedative prescribing for patients with the following characteristics:
      a. Patients with 3 or more unique prescribers of opioid and sedative therapy
      b. Patients with a prior history of sedative poisoning

   ACTION: The Committee recommended exploring tools beyond the lettering to providers and members including developing dashboards and to aggregate data to consider sorting patients by timeframe. Targeting those with chronic issues; consider adding a profile list of meds.
   Motion to approve, 2nd, 5 in favor, 3 opposed

V. PREFERRED DRUG LIST NEW BUSINESS

A. Antidepressant Class Update and New Drug Evaluation
   Dr. Sentena presented the proposal to:
   1. Make no changes to the PDL based on the review of clinical efficacy.
   2. Implement proposed prior authorization (PA) criteria for brexanolone and esketamine based on safety concerns.
   3. Evaluate comparative costs in executive session.

   ACTION: The Committee recommended adding a question to the esketamine safety edit to ask about history of substance abuse and recommended referral to the MHCAG to investigate recently approved drugs and optimal treatments for kids.
Motion to approve, 2nd, all in favor

B. Transthyretin Mediated Amyloidosis New Drug Evaluations
Dr. Herink presented the proposal to:
1. Create a PDL class for Drugs for hATTR.
2. Designate inotersen and patisiran as non-preferred medications.
3. Implement clinical PA criteria for patisiran and inotersen to ensure appropriate utilization.

ACTION: The Committee recommended adding a question on baseline disease severity and to document genotype.

Motion to approve, 2nd, all in favor

C. Atopic Dermatitis (AD) Class Update and Dupilumab Drug Update
Dr. Moretz presented the proposal to:
1. Remove dupilumab from the atopic dermatitis and topical antipsoriatic PA criteria and create a new PA document for dupilumab utilization in moderate-to-severe asthma and moderate-to-severe AD.
2. Update PA criteria for dupilumab based on FDA approved ages for AD and add renewal criteria.
3. Reorder questions in the dupilumab PA criteria to assess the prescribing practitioner at the beginning of the PA review.
4. Evaluate comparative costs in executive session.

ACTION: Motion to approve, 2nd, all in favor

D. Narcolepsy Agents DERP Summary and New Drug Evaluation
Dr. Servid presented the proposal to:
1. Add solriamfetol as a voluntary non-preferred product to the Other Stimulants class.
2. Designate sodium oxybate as non-preferred based upon the current review of efficacy and safety data.
3. Recommend implementation of a safety edit for solriamfetol
4. Update safety edits for modafinil/armodafinil to include assessment of first-line therapy in patients with OSA and alternative options for treatment in children.

ACTION: The Committee recommended adding a question to require trial and failure of first-line therapies (e.g., methylphenidate).

Motion to approve, 2nd, all in favor

Topics Deferred to a Future Meeting
E. Bone Metabolism Class Update and New Drug Evaluation

F. Aemcolo™ (rifamycin) New Drug Evaluation
VI. EXECUTIVE SESSION

Members Present: Mark Helm, MD, MBA, FAAP; Tracy Klein, PhD, FNP; William Origer, MD; Cathy Zehrung, RPh; James Slater, PharmD

Members Present by Phone: Stacy Ramirez, PharmD; David Pass, MD; Kelly Burnett, DO; Kathy Sentena, PharmD;

Staff Present: Roger Citron, RPh; David Engen, PharmD, CGP; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Renae Wentz, MD; Trevor Douglass, DC, MPH; Brandon Wells; Jennifer Torkelson; Jennifer Bowen; Victor Rojo

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Inhaled Short-acting Beta-agonists Literature Scan
   Recommendation: make no changes to the PDL
   
   **ACTION:** Motion to approve, 2nd, all in favor

B. Antidepressant Class Update and New Drug Evaluation
   Recommendation: make no changes to the PDL
   
   **ACTION:** Motion to approve, 2nd, all in favor

C. Atopic Dermatitis (AD) Class Update and Dupilumab Drug Update
   Recommendation: make no changes to the PDL
   
   **ACTION:** Motion to approve, 2nd, all in favor

VIII. ADJOURN